Join Us to Learn About
XPOVIO® (selinexor)

INTRODUCTION AND TRIAL OVERVIEW

A UNIQUE MECHANISM OF ACTION

ADVERSE EVENTS AND DOSING: SECTION 1

SECTION 2: TRIAL OVERVIEW AND EFFICACY

ADVERSE EVENTS: SECTION 2

KARYFORWARD AND PATIENT SUPPORT

QUESTION AND ANSWER

Please see full Prescribing Information.

Meet the Speakers

Michael W. Schuster, MD headshot

Michael W. Schuster, MD

Director, Stem Cell Transplantation and
Hematologic Malignancy Program
Stony Brook University School of Medicine


Hakan Kaya, MD headshot

Hakan Kaya, MD

Cancer Care Northwest
Director, Inland Northwest Myeloma/
Lymphoma and Transplant Program

Karyopharm logo

This iPub® is sponsored by Karyopharm Therapeutics Inc.
© 2020 Karyopharm Therapeutics Inc. All rights reserved.
US-XPOV-10/20-00009